What are the dosing, indications, contraindications, monitoring parameters, and common adverse effects of bempedoic acid for adults with elevated LDL‑cholesterol?

Bempedoic Acid: Clinical Overview

Bempedoic acid is dosed at 180 mg orally once daily (with or without food) for adults with elevated LDL-cholesterol who have atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH), particularly when used as adjunct to maximally tolerated statin therapy or in statin-intolerant patients. 1

FDA-Approved Indications

Bempedoic acid has two primary indications 1:

• Cardiovascular risk reduction: To reduce the risk of myocardial infarction and coronary revascularization in adults unable to take recommended statin therapy (including those not taking a statin) with established CVD or high CVD risk
• LDL-C lowering: As adjunct to diet, in combination with other LDL-C lowering therapies (or alone when combination therapy is not possible), to reduce LDL-C in adults with primary hyperlipidemia, including HeFH

Mechanism of Action

Bempedoic acid is an adenosine triphosphate-citrate lyase (ACL) inhibitor that blocks cholesterol synthesis upstream of HMG-CoA reductase in the liver. Critically, it requires activation by very long-chain acyl-CoA synthetase 1 (ACSVL1), which is expressed primarily in the liver—this explains why bempedoic acid does not cause the muscle-related adverse effects typical of statins. 2, 1

Dosing

• Standard dose: 180 mg orally once daily 2, 1
• Can be taken with or without food 1
• No dose adjustment needed for mild-to-moderate renal impairment (eGFR ≥30 mL/min/1.73 m²) or mild-to-moderate hepatic impairment (Child-Pugh A or B) 1
• Limited experience in severe renal impairment (eGFR <30 mL/min/1.73 m²); not studied in end-stage renal disease on dialysis 1
• Not studied in severe hepatic impairment (Child-Pugh C) 1

Expected LDL-C Reduction

When added to maximally tolerated statin therapy, bempedoic acid reduces LDL-C by 17-18% (placebo-corrected). 2 In statin-intolerant patients, reductions of 22-38% have been observed. 3, 4

When combined with ezetimibe as fixed-dose combination therapy, LDL-C reduction increases to approximately 38% (placebo-corrected). 2

Real-world data confirms these findings, with LDL-C reductions of 21% at 3 months for bempedoic acid monotherapy and 33% for the combination with ezetimibe. 4

Contraindications

History of serious hypersensitivity reaction to bempedoic acid or any excipients. 1

For the fixed-dose combination with ezetimibe, add: history of hypersensitivity to ezetimibe. 2

Warnings and Precautions

Hyperuricemia (Most Important)

Bempedoic acid increases serum uric acid levels. 2, 1

• Monitoring: Assess uric acid level before initiation and periodically as clinically indicated, especially if symptoms of hyperuricemia occur 2, 1
• Monitor for signs/symptoms of hyperuricemia and gout 1
• Initiate urate-lowering drugs as appropriate 2, 1
• In the CLEAR Outcomes trial, gout occurred in 3.2% of bempedoic acid patients vs 2.2% of placebo patients 5
• Risk is approximately 4 times higher in patients with previous gout diagnosis or elevated baseline uric acid 6

Tendon Rupture

Tendon rupture has occurred with bempedoic acid. 2, 1

• Discontinue immediately if tendon rupture occurs 2, 1
• Consider discontinuing if patient experiences joint pain, swelling, or inflammation 2, 1
• Avoid in patients with history of tendon disorders or tendon rupture 2, 1
• Advise patients to rest at first sign of tendinitis or tendon rupture and contact healthcare provider 2, 1
• In CLEAR Outcomes, tendinopathies including tendon rupture occurred in 2% of patients in both treatment groups 5

Common Adverse Effects

From primary hyperlipidemia trials (incidence ≥2% and more frequent than placebo) 2, 1:

• Upper respiratory tract infection
• Muscle spasms
• Hyperuricemia
• Back pain
• Abdominal pain or discomfort
• Bronchitis
• Pain in extremity
• Anemia
• Elevated liver enzymes

From cardiovascular outcomes trial (incidence ≥2% and 0.5% greater than placebo) 1:

• Hyperuricemia
• Renal impairment
• Anemia
• Elevated liver enzymes
• Muscle spasms
• Gout
• Cholelithiasis (2.2% vs 1.2% placebo) 5

Notably, unlike statins, bempedoic acid has a low incidence of musculoskeletal adverse events due to its liver-specific activation. 7

Monitoring Parameters

Based on the warnings and evidence:

1. Uric acid: Check before initiation and periodically as clinically indicated, especially if symptoms develop 2, 1
2. Liver enzymes: Monitor as clinically indicated 2, 1
3. LDL-C levels: Check at 4-6 weeks after initiation, then at 3 months 8
4. Renal function: Monitor as clinically indicated (small increases in BUN and creatinine reported) 6, 5
5. Hemoglobin: Monitor as clinically indicated (anemia reported) 1, 5
6. Clinical monitoring: Watch for signs/symptoms of tendinopathy, gout, and gallbladder disease 1, 5

Drug-Drug Interactions

Avoid concomitant use with:

• Simvastatin >20 mg daily 2, 1
• Pravastatin >40 mg daily 2, 1

For the combination product with ezetimibe, additional interactions include cyclosporine and fibrates. 2

Special Populations

Pregnancy

Discontinue when pregnancy is recognized unless benefits outweigh potential risks to the fetus. 2 No available data on use in pregnant women to evaluate drug-associated risk of major birth defects, miscarriage, or adverse maternal/fetal outcomes. 2 Based on mechanism of action, may cause fetal harm. 1

Lactation

Breastfeeding is not recommended. 1

Geriatric Use

No dose adjustment necessary. In CLEAR Outcomes, 59% of patients were ≥65 years and 15% were ≥75 years. No overall differences in safety or effectiveness observed between older and younger patients. 1 Efficacy and safety in patients ≥75 years were comparable to younger age groups regardless of background statin use. 9

Cardiovascular Outcomes Evidence

The CLEAR Outcomes trial demonstrated that bempedoic acid significantly reduced the primary endpoint (4-component MACE: CV death, nonfatal MI, nonfatal stroke, or coronary revascularization) in statin-intolerant patients at high cardiovascular risk. 7, 5 This trial included 13,970 patients followed for a median of 3.4 years. 5

Important caveat: Current evidence does not demonstrate a reduction in deaths from cardiovascular causes specifically. 6

Clinical Positioning

According to the 2022 ACC Expert Consensus Decision Pathway [2-2] and 2024 International Lipid Expert Panel recommendations 8:

• Use as adjunct to maximally tolerated statin therapy in patients with ASCVD or HeFH who have not achieved LDL-C goals
• Consider for statin-intolerant patients as an oral alternative that avoids muscle-related side effects
• Can be used in upfront combination therapy with statins and ezetimibe in very high-risk patients (triple therapy approach) 8
• May be combined with PCSK9 inhibitors for quadruple therapy in extreme-risk patients not at goal 8

Practical Considerations

• Cost and prior authorization: Often requires prior authorization 2
• Pill burden: Once-daily dosing improves adherence 2
• Adherence: Real-world data shows greatest LDL-C reductions with continuous use (no therapy gap >45 days), emphasizing importance of long-term adherence 4
• Early efficacy: LDL-C reductions are evident by 3 months and sustained over 12 months 4

Common Pitfalls to Avoid

1. Do not deescalate therapy if low or very low LDL-C levels are achieved and therapy is well-tolerated—maintain treatment per "lower is better for longer" principle 8
2. Screen for gout history and baseline uric acid before initiating, as risk is substantially higher in these patients 6
3. Do not exceed simvastatin 20 mg or pravastatin 40 mg when used concomitantly 1
4. Counsel patients about tendon rupture risk and instruct them to stop medication and seek care immediately if symptoms occur 1
5. Monitor for cholelithiasis, particularly in patients with risk factors for gallbladder disease 5